NCT01818024 - A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2013

Primary Completion Date

October 25, 2013

Study Completion Date

October 25, 2013

Conditions

Respiratory Disorders

Interventions

DRUG

Single IV dose of GSK2862277

GSK2862277 solution available in a 40 mg vial for IV administration.

DRUG

Matching placebo single dose IV infusion

Matching placebo solution available for IV administration.

DRUG

Single IH dose of GSK2862277

GSK2862277 nebulised solution available in a 40 mg vial for IH administration.

DRUG

Matching placebo single dose IH

Matching placebo nebulised solution available for IH administration.

DRUG

Repeat IV dose of GSK2862277

GSK2862277 solution available in a 40 mg vial for IV administration.

DRUG

Matching placebo repeat dose IV infusion

Matching placebo solution available for IV administration.

DRUG

Repeat IH dose selected of GSK2862277 from Part 2

GSK2862277 nebulised solution available in a 40 mg vial for IH administration.

DRUG

Matching placebo repeat dose IH

Matching placebo nebulised solution available for IH administration.

Trial Locations (1)

GSK Investigational Site, Harrow